医学
多神经根神经病
格林-巴利综合征
神经学
儿科
重症监护医学
先天性肌无力综合征
静脉注射免疫球蛋白
呼吸系统
重症肌无力
神经传导
体格检查
麻醉学
反射减退
内科学
神经系统检查
外科
治疗性血浆置换
临床试验
物理疗法
血浆置换术
麻痹
颅神经
麻醉
鉴别诊断
出处
期刊:Continuum
[Lippincott Williams & Wilkins]
日期:2026-10-01
卷期号:32 (5): 1392-1415
被引量:3
标识
DOI:10.1212/cont.0000000000001764
摘要
OBJECTIVE: This article reviews the epidemiology, clinical symptoms, examination findings, pathogenesis, diagnostic criteria, and recent guidelines of Guillain-Barré syndrome (GBS) and its variants, including information on outcome measures, management, and ongoing research. LATEST DEVELOPMENTS: CSF examination and electrodiagnostic testing are useful in some cases to support the diagnosis, particularly when GBS variants are suspected. Antibody testing is of limited value in typical sensorimotor GBS, but useful when GBS variants and nodopathies are considered. According to evidence-based guidelines for the diagnosis and treatment of GBS developed by the European Academy of Neurology and Peripheral Nerve Society, IV immunoglobulin (IVIg) or plasma exchange are the recommended treatment options. The guidelines recommend against using a second IVIg course, or corticosteroids or plasma exchange followed immediately by IVIg. For treatment of pain, gabapentinoids, tricyclic antidepressants, or carbamazepine have been recommended. The Modified Erasmus GBS outcome score and Modified Erasmus GBS Respiratory Insufficiency Score have been recommended. Research is ongoing to find new treatment options. ESSENTIAL POINTS: GBS is a life-threatening neuromuscular emergency seen frequently worldwide. Symptom progression for less than 4 weeks and findings of sensorimotor deficits and areflexia are required to make the diagnosis. Some patients may present with pain, cranial nerve involvement, autonomic dysfunction, or respiratory insufficiency. If progression continues after 8 weeks from onset, consider the diagnosis of acute-onset chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), which is seen in 5% of patients initially diagnosed with GBS. Approximately 20% of patients have significant residual deficits and poor prognosis despite receiving available treatments.
科研通智能强力驱动
Strongly Powered by AbleSci AI